Buy Crypto Markets Spot FuturesGOLD Earn Event Center

Hemab Therapeutics Holdings, Inc. (COAG)

NASDAQ

$29.32

$-5.02

(-14.78%)

Hemab Therapeutics Holdings, Inc. (COAG) Live Price Chart

Page last updated: 2026-05-04 17:08:13

Key Market Data

Market Cap	$1.15B
Open	$30.87
High	$36.61
Low	$27.00
Previous Close	$34.00
Price Change	$-5.02
Percentage Change	-14.78%
Volume	444K

Hemab Therapeutics Holdings, Inc. (COAG) Stock Price Today

Hemab Therapeutics Holdings, Inc. (COAG) is currently trading at $29.32 as of 2026-05-04 17:08:13, reflecting a -14.78% move ($-5.02) from the previous close.

In the short term, the stock has returned -13.75% over the past four weeks. Over the last 12 months, Hemab Therapeutics Holdings, Inc. has recorded a -13.75% price change, indicating a Weak performance relative to the broader market.

Hemab Therapeutics Holdings, Inc. (COAG) 7-Day Stock Price Changes

Over the past seven days, Hemab Therapeutics Holdings, Inc. has traded within a short-term range shaped by market sentiment in the sector. During this period, the stock moved from its previous closing price of $27.00 to the latest recorded price of $29.32, reflecting an intraday change of -14.78%. Daily movements highlight shifts in trading volume (443,713), investor positioning, and reactions to macroeconomic updates.

From a momentum standpoint, COAG has delivered a -13.75% return over the past month and a -13.75% change in the last 12 months, indicating a Weak trend relative to its broader sector peers.

How to Buy Hemab Therapeutics Holdings, Inc. (COAG)

You can buy and trade COAG on MEXC in three simple steps:

Step 1: Create and Verify Your MEXC Account

Sign up on MEXC and complete the required identity verification (KYC). This ensures full access to trading features and secure funding options.

Step 2: Deposit Funds Into Your Account

Choose your preferred payment method to add USDT or other supported assets to your MEXC wallet. Depositing crypto is the fastest way to get started.

Step 3: Search for COAG and Execute Your Trade

Open the trading page, enter COAG in the search bar, select the amount of COAG you would like to purchase. Place a market order for instant execution or a limit order to buy at your target price.

What is Hemab Therapeutics Holdings, Inc. (COAG)?

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Hemab Therapeutics Holdings, Inc. Information

Industry	--
Employees	--
Sector	--
Company Website	https://www.hemab.com

Frequently Asked Questions (FAQ)

1.What is the current share price of Hemab Therapeutics Holdings, Inc.?

The latest trading price for Hemab Therapeutics Holdings, Inc. (Common Stock) is $ 29.32, compared with a previous closing price of $ 34.00. That means the stock has moved -14.78% so far today. Intraday price updates and recent trading activity for COAG can be tracked on the live chart and quote section on this page.

2.Is Hemab Therapeutics Holdings, Inc. stock going up or down?

Looking at recent performances, COAG has returned -13.75% over the past month, -13.75% over the last six months and -13.75% over the past year. These figures capture share-price changes only, not the impact of dividends. Together they describe Weak price momentum for Hemab Therapeutics Holdings, Inc. stock, but keep in mind that past returns do not guarantee future results.

3.Where does COAG currently sit relative to its 52-week high and low?

In the most recent 52-week period, Hemab Therapeutics Holdings, Inc. has traded between a low of $ 27.00 and a high of $ 36.61. This 52-week range helps show where today's share price sits relative to its recent highs and lows, and is often used by investors to judge stock volatility, potential support and resistance levels, and whether COAG is currently nearer the top or the bottom of its one-year trading band.

4.How is Hemab Therapeutics Holdings, Inc. classified by sector and industry?

Hemab Therapeutics Holdings, Inc. is classified in the -- sector. In practice, this means Hemab Therapeutics Holdings, Inc. is grouped with other companies that serve similar end-markets and operate under comparable competitive and regulatory conditions. For investors, knowing COAG’s sector helps with portfolio diversification, peer comparisons, and understanding how broader trends affecting the -- sector could influence Hemab Therapeutics Holdings, Inc.’s performance.

5.Where is Hemab Therapeutics Holdings, Inc. listed and how large is it by market value?

Hemab Therapeutics Holdings, Inc. is listed on the NASDAQ stock exchange in United States. Based on a market capitalization of $ 1.15B, the company is classified as a Small-cap stock. Market cap gives a quick sense of Hemab Therapeutics Holdings, Inc.'s size and importance in the equity market and is often used by investors and index providers when constructing portfolios or benchmarks.

6.What does COAG's EPS tell investors about its profitability?

Trailing-twelve-month EPS of -- summarises how much profit Hemab Therapeutics Holdings, Inc. has generated per share over the last year. Rising EPS over time can signal improving profitability or effective share repurchases, while flat or declining EPS may point to slower growth or margin pressure. EPS is a key input into valuation metrics such as P/E and is often monitored closely around earnings announcements.

7.How can I track Hemab Therapeutics Holdings, Inc.'s financial performance over time?

To follow Hemab Therapeutics Holdings, Inc.'s financial performance, investors typically review its quarterly and annual reports, which include detailed income statements, balance sheets and cash-flow statements. Combining these filings with key market data shown on this page—such as share price trends, P/E and dividend yield—provides a more complete view of how COAG is performing and how the market is responding.

8.When is Hemab Therapeutics Holdings, Inc. expected to report earnings?

Hemab Therapeutics Holdings, Inc.'s next scheduled earnings release is currently expected on -- (the date may be updated by the company). Earnings announcements often act as important catalysts for COAG, as they provide updated information on revenue, profitability and management's outlook.

9.What usually comes out in Hemab Therapeutics Holdings, Inc.'s earnings reports?

Hemab Therapeutics Holdings, Inc.'s earnings reports typically include headline figures such as revenue, net income and EPS, along with commentary on segment performance, margins, cash flow and guidance for future periods. Investors compare these results with market expectations and prior periods to assess whether COAG is meeting, beating or missing expectations.

10.How can I stay informed about Hemab Therapeutics Holdings, Inc.'s results and guidance?

You can stay up to date on Hemab Therapeutics Holdings, Inc. by reviewing its quarterly earnings releases, listening to or reading transcripts of earnings calls, and following company news and filings. Pairing this fundamental information with the price and return data for COAG on this page helps you see how new information is being reflected in the stock.

11.Does Hemab Therapeutics Holdings, Inc. pay a regular cash dividend to its shareholders?

Hemab Therapeutics Holdings, Inc. Non-paying. Based on the latest information, the stock has an indicated annual cash dividend of -- per share and a current dividend yield of -- at the recent share price. Dividends are typically paid --, although the board can change the dividend policy at any time. Income-focused investors often monitor COAG's dividend level, payment frequency and any announcements about future dividends when assessing the stock's appeal as a dividend-paying investment.

12.What are the current dividend yield and dividend payout ratio for COAG?

Based on the latest earnings data, COAG has a dividend yield of -- and a dividend payout ratio of --. The dividend yield shows how much cash return an investor receives from dividends each year relative to the current share price, helping assess whether Hemab Therapeutics Holdings, Inc. is an attractive income stock. The dividend payout ratio measures what percentage of earnings Hemab Therapeutics Holdings, Inc. distributes to shareholders as dividends versus how much it retains to reinvest in the business, which is an important indicator of dividend sustainability and room for future dividend growth.

13.What kind of business is Hemab Therapeutics Holdings, Inc.?

Hemab Therapeutics Holdings, Inc. is a publicly traded company in the -- industry within the -- sector. It generates revenue from products and services related to this core business area, and investors can find a detailed description of its operations, strategy and geographic exposure in the company's annual report and other regulatory filings.

14.How is COAG valued in terms of P/E ratio and EPS?

Hemab Therapeutics Holdings, Inc. currently trades at a price-to-earnings (P/E) ratio of --, based on trailing-twelve-month earnings per share (EPS) of --. P/E is calculated by dividing the share price by EPS and shows how much investors are paying today for each unit of Hemab Therapeutics Holdings, Inc.'s earnings. Comparing COAG's P/E and EPS to those of other -- companies can help investors judge whether its valuation looks rich or attractive.

Explore More US Stocks

Top 5 Cryptocurrencies

Explore the cryptocurrencies with the highest market capitalization

BTC

ETH

Disclaimer

The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.

COAG-to-USD Calculator

Amount

COAG

USD

1 COAG = 29.324 USD